Literature DB >> 23160322

Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.

Ahad A Sadiq1, Ravi Salgia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23160322     DOI： 10.1097/JTO.0b013e31826df03e

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  2 in total

1.  Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

Authors:  Daniel Morgensztern; Meghan J Campo; Suzanne E Dahlberg; Robert C Doebele; Edward Garon; David E Gerber; Sarah B Goldberg; Peter S Hammerman; Rebecca S Heist; Thomas Hensing; Leora Horn; Suresh S Ramalingam; Charles M Rudin; Ravi Salgia; Lecia V Sequist; Alice T Shaw; George R Simon; Neeta Somaiah; David R Spigel; John Wrangle; David Johnson; Roy S Herbst; Paul Bunn; Ramaswamy Govindan
Journal:  J Thorac Oncol       Date:  2015-01       Impact factor: 15.609

Review 2.  Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies.

Authors:  Nehad M Ayoub; Dalia R Ibrahim; Amer E Alkhalifa
Journal:  Med Oncol       Date:  2021-10-19       Impact factor: 3.064
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.